Research Overview

Drug Discovery

Drug Discovery's vision is to develop log scale improvements to accelerate and de-risk the process of drug discovery, with the long-term goal of doubling the success rate in clinical development. The program objective is to propel BII to the leading edge of transformative computational innovation in bringing new medicines to patients, ranging from the discovery of novel disease targets to the design & optimization of therapeutics and the selection of patient populations, as well as positioning the institute as a premier hub for public-private collaboration in biopharma, attracting sustained research funding and generating high-impact assets with both commercial and societal value.

Cellular Biotech

Cellular Biotech program's mission is to pioneer the research and development of AI-powered and data-driven biotechnologies, including novel data analytics platforms, AI/ML models, markers, or assays, as well as their translation and commercialization and into practical solutions for disease modeling and diagnosis, chemical/biomolecule assessments, therapeutic development, and precision medicine

The program's current scientific focuses include:

1. Multi-modal AI models, foundation models, digital twins, or other advanced AI methods for disease modeling and target discovery and therapeutic development
2. Predictive and automated in vitro or in silico assays, markers, or tools for disease diagnosis, chemical/biomolecule assessment, and precision medicine Data management and analytics platforms for cellular/tissue images, biochemical assays, mass spectra, and molecular structures

Pandemic Preparedness (GDSC)

The Pandemic Preparedness programme strengthens readiness for emerging infectious disease threats through genomic surveillance, data curation, computational analysis, and public health intelligence. Based in BII's GDSC, the team develops and maintains resilient data platforms, analytical tools, dashboards, and reporting workflows that transform pathogen genome data into timely, actionable evidence. Our work supports the rapid detection, characterization, and monitoring of priority and novel pathogens. By combining high-quality genomic and epidemiological data with bioinformatics, phylodynamics, structural modelling, and AI-enabled methods, we help researchers and public health partners identify mutations, emerging variants, transmission patterns, and potential impacts on diagnostics, therapeutics, and vaccines.